News Pfizer, Valneva Lyme vaccine starts review in Europe After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.
News Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.
News France probes side effects with Valneva's chikungunya jab France's national public health agency has halted dosing of Valneva's chikungunya vaccine in older people while it investigates a safety signal.
News Bavarian Nordic chikungunya vaccine gets FDA okay There are now two vaccines to protect against chikungunya approved for use in the US, after Bavarian Nordic gets the green light for Vimkunya.
News CHMP backs Bavarian Nordic's chikungunya jab Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.
News Data builds behind Valneva, Pfizer's Lyme disease vaccine New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.